60 Degrees Pharmaceuticals, Inc. Warrant financials
$0.0324+28.26%
Close Sep 25, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $207.9K | $162.1K | $316.4K | $528.6K | $307.9K | $256.3K | $272.2K | $148.1K | $125.7K | $135.3K | $42.7K | $126.8K |
| Gross profit | $56.8K | $76.4K | $195.7K | -$9.1K | $257.8K | $183.0K | $154.2K | $36.4K | $36.1K | $69.9K | -$103.5K | $55.6K |
| Gross margin | 27.3% | 47.1% | 61.9% | −1.7% | 83.7% | 71.4% | 56.6% | 24.6% | 28.7% | 51.6% | −242.5% | 43.8% |
| Operating income | -$2.3M | -$2.1M | -$1.9M | -$2.3M | -$1.6M | -$1.9M | -$2.1M | -$2.1M | -$4.2M | -$1.3M | -$1.9M | -$1.5M |
| Net income | -$2.4M | -$2.2M | -$1.6M | -$2.4M | -$1.8M | -$2.0M | -$2.2M | -$2.3M | -$4.3M | $308.7K | -$2.1M | $4.1M |
| Net margin | −1152.6% | −1362.5% | −495.6% | −462.2% | −598.7% | −782.2% | −800.7% | −1534.0% | −3410.9% | 228.1% | −4864.0% | 3227.5% |
| Diluted EPS | $-0.90 | $-1.28 | — | $-2.64 | $-5.01 | $-6.25 | $-9.10 | $-18.60 | $-84.48 | $7.32 | $-38.53 | $182.60 |
| EBITDA | -$2.3M | -$2.0M | -$1.7M | -$2.3M | -$1.7M | -$1.9M | $1.5M | -$2.1M | -$4.2M | -$1.3M | -$1.9M | -$1.5M |
| Operating cash flow | -$2.2M | -$2.7M | -$1.7M | -$2.1M | -$1.5M | -$1.6M | -$1.6M | -$1.7M | -$1.2M | -$1.1M | -$63.7K | -$3.8M |
| Free cash flow | -$2.2M | -$2.8M | -$1.8M | -$2.1M | -$1.5M | -$1.6M | -$1.6M | -$1.7M | -$1.3M | -$1.1M | -$119.5K | -$3.8M |
| Diluted shares | 2.7M | 1.7M | — | 0.9M | 0.4M | 0.3M | 0.2M | 0.1M | 0.1M | 0.0M | 0.1M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.0M | $3.3M | $1.5M | $4.1M | $2.0M | $3.5M |
| Short-term investments | $0.00 | $0.00 | $1.2M | $0.00 | $0.00 | $0.00 |
| Total debt | $149.2K | $143.2K | $144.0K | $145.0K | $145.5K | $146.5K |
| Total assets | $4.3M | $6.8M | $5.4M | $6.7M | $4.2M | $6.0M |
| Total liabilities | $1.8M | $2.0M | $2.0M | $2.3M | $1.8M | $1.9M |
| Shareholders' equity | $2.5M | $4.7M | $3.4M | $4.3M | $2.3M | $4.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology